Aditya Birla Sunlife Life Pharma & Healthcare IDCW Reinvest Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹1,000

Aditya Birla Sunlife Life Pharma & Healthcare IDCW Reinvest Direct Plan

NAV
₹22.2400
-5.08%
(23 Feb)
AUM
812 Cr
TER
1.02%
Risk
Very High Risk
Insights
Total Expense Ratio (TER) is in the bottom 25% of comparable funds
Net Asset Value (NAV) is above its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+31.2%
+31.2%
+31.2%
+29.2%
+10.7%
3Y
+36.0%
+36.0%
+36.0%
+33.5%
+24.6%
5Y
+29.4%
+29.4%
+29.4%
+27.5%
+15.6%
ALL
+12.8%
+12.8%
+12.8%
+16.8%
+19.9%
VOL
20.0%
20.0%
20.0%
20.1%
16.7%
TER
0.8%
0.8%
0.8%
0.9%
1.0%
AUM
₹5,980 Cr
₹5,980 Cr
₹5,980 Cr
₹1,492 Cr
₹812 Cr
INFO
0.64
0.64
0.64
0.83
1.19
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Aditya Birla Sunlife Life Pharma & Healthcare IDCW Reinvest (DR)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Jan
Top holdings
Sun Pharmaceuticals Industries Ltd
12.9%
Apollo Hospitals Enterprise Ltd
7.3%
Torrent Pharmaceuticals Ltd
5.0%
J.B. Chemicals & Pharmaceuticals Ltd
4.8%
Ajanta Pharma Ltd
4.4%
Abbott India Ltd
4.4%
Aurobindo Pharma Ltd
4.3%
Lupin Ltd
4.1%
Ipca Laboratories Ltd
4.0%
Fortis Healthcare Ltd
4.0%
Top industry exposure
Healthcare
97.1%
Basic Materials
0.9%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹1,000
Additional lumpsum
₹1,000
Portfolio turnover
32%
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes’ objectives will be achieved.
Fund manager(s)
Dhaval Shah

FAQs